$18.41
+0.16
(+0.88%)▲
Insights on Hutchison China Meditech Limited
Revenue is down for the last 3 quarters, 266.43M → 152.56M (in $), with an average decrease of 21.4% per quarter
Netprofit is down for the last 3 quarters, 84.27M → -33.88M (in $), with an average decrease of 70.1% per quarter
In the last 1 year, Neurocrine Biosciences Inc. has given 36.8% return, outperforming this stock by 11.5%
In the last 3 years, Neurocrine Biosciences Inc. has given 44.8% return, outperforming this stock by 83.8%
1.63%
Downside
Day's Volatility :3.31%
Upside
1.71%
41.99%
Downside
52 Weeks Volatility :48.48%
Upside
11.19%
Period | Hutchison China Meditech Limited | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 31.77% | 2.0% | 0.0% |
6 Months | 3.99% | 11.7% | 0.0% |
1 Year | 25.26% | 5.8% | 1.3% |
3 Years | -39.0% | 14.2% | -22.1% |
Market Capitalization | 2.9B |
Book Value | $0.86 |
Earnings Per Share (EPS) | 0.6 |
PE Ratio | 28.23 |
PEG Ratio | 0.0 |
Wall Street Target Price | 28.47 |
Profit Margin | 12.03% |
Operating Margin TTM | -30.57% |
Return On Assets TTM | 1.0% |
Return On Equity TTM | 14.65% |
Revenue TTM | 838.0M |
Revenue Per Share TTM | 4.93 |
Quarterly Revenue Growth YOY | 36.0% |
Gross Profit TTM | -271.6M |
EBITDA | 26.6M |
Diluted Eps TTM | 0.6 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.88 |
EPS Estimate Next Year | -1.04 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 54.64%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 214.1M | ↓ 11.23% |
Net Income | -74.8M | ↑ 179.78% |
Net Profit Margin | -34.94% | ↓ 23.86% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 204.9M | ↓ 4.31% |
Net Income | -144.4M | ↑ 93.01% |
Net Profit Margin | -70.47% | ↓ 35.53% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 228.0M | ↑ 11.27% |
Net Income | -194.6M | ↑ 34.76% |
Net Profit Margin | -85.34% | ↓ 14.87% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 356.1M | ↑ 56.21% |
Net Income | -227.7M | ↑ 17.01% |
Net Profit Margin | -63.93% | ↑ 21.41% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 426.4M | ↑ 19.73% |
Net Income | -410.1M | ↑ 80.16% |
Net Profit Margin | -96.18% | ↓ 32.25% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 838.0M | ↑ 96.52% |
Net Income | 100.8M | ↓ 124.57% |
Net Profit Margin | 12.03% | ↑ 108.21% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 112.2M | ↑ 11.04% |
Net Income | -99.0M | ↑ 21.56% |
Net Profit Margin | -88.24% | ↓ 7.63% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 112.2M | ↑ 0.0% |
Net Income | -99.0M | ↑ 0.0% |
Net Profit Margin | -88.24% | ↑ 0.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 266.4M | ↑ 137.51% |
Net Income | 84.3M | ↓ 185.14% |
Net Profit Margin | 31.63% | ↑ 119.87% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 266.4M | ↑ 0.0% |
Net Income | 84.3M | ↑ 0.0% |
Net Profit Margin | 31.63% | ↑ 0.0% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 152.6M | ↓ 42.74% |
Net Income | -33.9M | ↓ 140.21% |
Net Profit Margin | -22.21% | ↓ 53.84% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 152.6M | ↑ 0.0% |
Net Income | -33.9M | ↑ 0.0% |
Net Profit Margin | -22.21% | ↑ 0.0% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 532.1M | ↓ 11.01% |
Total Liabilities | 119.9M | ↑ 6.11% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 465.1M | ↓ 12.59% |
Total Liabilities | 152.2M | ↑ 26.99% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 724.1M | ↑ 55.68% |
Total Liabilities | 205.2M | ↑ 34.79% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.4B | ↑ 89.56% |
Total Liabilities | 333.1M | ↑ 62.38% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 1.0B | ↓ 25.0% |
Total Liabilities | 392.6M | ↑ 17.84% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 1.3B | ↑ 24.32% |
Total Liabilities | 536.4M | ↑ 36.63% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.0B | ↓ 13.81% |
Total Liabilities | 392.6M | ↑ 14.63% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.3B | ↑ 26.04% |
Total Liabilities | 497.5M | ↑ 26.72% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.3B | ↑ 0.0% |
Total Liabilities | 497.5M | - |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.3B | ↓ 1.37% |
Total Liabilities | 536.4M | ↑ 7.82% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.3B | ↑ 0.0% |
Total Liabilities | 536.4M | ↑ 0.0% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -32.8M | ↑ 267.29% |
Investing Cash Flow | 43.8M | ↓ 116.78% |
Financing Cash Flow | -8.2M | ↓ 103.01% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -80.9M | ↑ 146.33% |
Investing Cash Flow | 119.0M | ↑ 172.05% |
Financing Cash Flow | -1.5M | ↓ 81.86% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -62.1M | ↓ 23.29% |
Investing Cash Flow | -125.4M | ↓ 205.39% |
Financing Cash Flow | 296.4M | ↓ 19954.92% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -204.2M | ↑ 229.04% |
Investing Cash Flow | -306.3M | ↑ 144.19% |
Financing Cash Flow | 650.0M | ↑ 119.28% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -268.6M | ↑ 31.52% |
Investing Cash Flow | 296.6M | ↓ 196.82% |
Financing Cash Flow | -82.8M | ↓ 112.73% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -89.4M | ↑ 98.91% |
Investing Cash Flow | 18.4M | ↓ 85.8% |
Financing Cash Flow | -4.1M | ↓ 89.11% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 167.6M | ↓ 287.52% |
Investing Cash Flow | 18.4M | ↑ 0.0% |
Financing Cash Flow | -766.6M | ↑ 18770.68% |
Sell
Neutral
Buy
Hutchison China Meditech Limited is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Hutchison China Meditech Limited | 8.57% | 3.99% | 25.26% | -39.0% | -37.61% |
Neurocrine Biosciences Inc. | -0.11% | 29.44% | 36.85% | 41.85% | 79.67% |
Haleon Plc Spon Ads | -0.24% | 1.82% | -5.93% | 13.5% | 13.5% |
Zoetis Inc. | -10.88% | -10.51% | -15.19% | -11.92% | 47.93% |
Viatris Inc. | -3.97% | 24.7% | 23.75% | -16.16% | -30.48% |
Catalent, Inc. | -0.8% | 31.9% | 32.08% | -51.57% | 25.36% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Hutchison China Meditech Limited | 28.23 | 28.23 | 0.0 | -0.88 | 0.15 | 0.01 | NA | 0.86 |
Neurocrine Biosciences Inc. | 53.44 | 53.44 | 0.44 | 4.78 | 0.13 | 0.09 | NA | 22.61 |
Haleon Plc Spon Ads | 29.86 | 29.86 | 1.69 | 0.45 | 0.07 | 0.04 | 0.03 | 1.8 |
Zoetis Inc. | 28.76 | 28.76 | 2.58 | 5.8 | 0.5 | 0.13 | 0.01 | 10.9 |
Viatris Inc. | 225.0 | 225.0 | NA | 2.78 | 0.0 | 0.03 | 0.04 | 17.05 |
Catalent, Inc. | 211.02 | NA | 2.06 | 0.48 | -0.3 | -0.01 | NA | 20.41 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Hutchison China Meditech Limited | Buy | $2.9B | -37.61% | 28.23 | 12.03% |
Neurocrine Biosciences Inc. | Buy | $13.3B | 79.67% | 53.44 | 13.23% |
Haleon Plc Spon Ads | Buy | $38.2B | 13.5% | 29.86 | 9.28% |
Zoetis Inc. | Buy | $66.5B | 47.93% | 28.76 | 27.43% |
Viatris Inc. | Hold | $13.4B | -30.48% | 225.0 | 0.35% |
Catalent, Inc. | Hold | $10.1B | 25.36% | 211.02 | -31.77% |
Schroder Investment Management Group
General Atlantic Llc
Allianz Asset Management AG
Bellevue Group AG
Goldman Sachs Group Inc
JANE STREET GROUP, LLC
HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs.
Organization | Hutchison China Meditech Limited |
Employees | 1988 |
CEO | Mr. Chi Keung To ACGI, B.Sc., M.B.A. |
Industry | Health Technology |
Dnp Select Income Closed Fund
$18.41
+0.88%
Masonite International Corp
$18.41
+0.88%
Zillow Group, Inc. - Class C Shares
$18.41
+0.88%
Edgio Inc.
$18.41
+0.88%
Papa John's International Inc.
$18.41
+0.88%
Jpmorgan Betabuilders Europe Etf
$18.41
+0.88%
Marqeta, Inc.
$18.41
+0.88%
Endeavor Group Holdings, Inc.
$18.41
+0.88%
Global X Nasdaq 100 Covered Call Etf
$18.41
+0.88%